he use of coronary stents for the treatment of stenotic coronary artery disease has increased markedly in the last several years. Coronary stents have improved both the short and long-term clinical outcomes of percutaneous coronary intervention. 1,2 Nevertheless, the risk of subacute thrombosis and the incidence of in-stent restenosis remains the major limitations of coronary stent implantation. A number of strategies have been adopted in an effort to reduce those risks. 3-5 Stent-based approaches include the attachment of anti-coagulants such as heparin 6 or the use of radioactive stents 7 to reduce local cell proliferation. Simply coating stents with biocompatible polymers to mask the underlying thrombotic metal surface is another approach. Earlier studies on stents coated with a variety of biodegradable and biostable polymers showed marked inflammatory responses and subsequent neointimal thickening. 8 However, both in vitro and in vivo research have demonstrated that phosphorylcholine (PC)-based polymers are effective in improving the biocompatibility of inert materials. 9-11 Phosphorylcholine is a major component of the outer layer head-groups of the cell membrane. These characteristics lend themselves to the application of this material as a biocompatible coating for stents.
Stent Design
Two variations of the BiodivYsio PC-coated stent were used in the present study: the open cell type (OC) for vessels 3.0 mm in diameter or larger, and the small vessel type (SV) for vessels less than 3.0 mm in diameter. The stent tube diameter before dilatation of the OC is 1.6 mm and for the SV it is very small at 1.0 mm. The stent strut thickness of the OC is 91.44 m and for the SV it is very thin at 60.96 m. The OC is available in diameters of 3.0, 3.5, and 4.0 mm and in lengths of 15, 18, and 28 mm. The SV is available in diameters of 2.0 and 2.5 mm and in lengths of 10 and 18 mm.
This stent is a balloon-expandable slotted tube stent laser cut from 316L stainless steel based on an interlocking arrowhead design. Its design enables both maximum longitudinal flexibility and radial strength. Six elements arranged circumferentially permit symmetric expansion. This stent is coated with a PC-containing copolymer to confer biocompatibility.
Stent Implantation
All patients were premedicated with 100-300 mg of aspirin per day and 200 mg of ticlopidine per day orally for at least 12 h prior to implantation. Heparin was given intravenously as a bolus dose of 10,000 IU at the beginning of the procedure and later as required to maintain the activated clotting time >300 s. Infusion of glycoprotein IIb/IIIa platelet inhibiter was not given to all patients. Intracoronary isosorbide dinitrate 2.5-5.0 mg was administered immediately prior to baseline angiography and at post-stent deployment final angiography.
The procedure was carried out in accordance with standard techniques. After predilatation, the stent was deployed at the treatment site. The choice of angioplasty and stent delivery balloon was made by the operator during the procedure according to a visual assessment of the reference diameter (RD) of the vessel in which the procedure was being carried out. Intravascular ultrasound (IVUS) was not available for the selection of balloon or stent sizes. Procedural success was defined as less than 30% residual stenosis after stent implantation. After stent implantation, administration of aspirin was continued indefinitely and ticlopidine was prescribed for 28 days in all cases.
Quantitative Coronary Angiographic (QCA) Analysis
QCA measurements were performed pre-procedurally, post-stent deployment, and at 6-month follow-up by an experienced investigator who was not involved in the angioplasty procedure. QCA analysis was performed using the already validated automated edge detection computer algorithm and commercially available Cardiovascular Angiography Analysis System II. 12 Each lesion was analyzed in 2 approximately orthogonal projections selected for maximal avoidance of superimposition and vessel foreshortening. The distal end of the guiding catheter was used for calibration in each analyzed projection. Lesion length, RD, minimal lumen diameter (MLD), percentage diameter stenosis (%DS) before and after stent implantation and at 6-month follow-up were measured. The stent/artery ratio on QCA was calculated by dividing the maximal diameter of the inflated balloon by the RD. Angiographic restenosis was defined as >50% DS at 6-month follow-up angiography at any point within the stented segment or in the 3 mm proximal or 3 mm distal to the edge or the nearest side branch. Lesions were characterized according to the modified American College of Cardiology/American Heart Association criteria.
Clinical and Angiographic Follow-up
All patients were asked to return to have clinical followup studies at 30 days and 6 months after the stent deployment. Coronary angiography was requested to be performed at 6 months in all patients. The endpoint of the present study was the occurrence of any of the following events: acute or subacute stent thrombosis, AMI, repeat coronary intervention, coronary artery bypass grafting (CABG), angiographic restenosis at 6 months, or death.
Statistical Analysis
Continuous variables are expressed as means ± standard deviation. Discrete variables are expressed as counts and percentages. Paired student's t-test or Welch's t-test were used for comparisons of each variable. Results were considered statistically significant at p<0.05.
Results

Baseline Data
From August 2001 to April 2003, 130 patients with lesions were treated with this stent. Table 1 represents the baseline clinical characteristics of the study population. Ninety patients underwent elective stenting and 40 patients underwent bailout stenting of small vessels. There were 101 males and 29 females with a mean age of 67±10 years with 35% of the patients having diabetes mellitus, 65% with hypertension, 41% with hyperlipidemia, and 24% were current smokers. Procedural Results Table 2 describes baseline angiographic characteristics for the patients in the current study; 8% of lesions were restenotic, 24% were bifurcation lesions, 7% were calcified, and 24% were tortuous. More than half of the patients had type B2/C complex lesions. Stent placement was 34% in the left anterior descending coronary artery, 29% in the left circumflex coronary artery, 36% in the right coronary artery, and 1% in the high lateral coronary branch.
Implanted stent sizes are shown in Table 3 . The majority of OC stents were 3.0 or 3.5 mm diameter, and 15 or 18 mm in length with 4.0 mm diameter stents used at 6.1%, and 28 mm length stent were used at 5.3% of the implants. However, the majority of SV stent implants were 2.5 mm in diameter and those of 2.0 mm in diameter were used in 7.7%.
Procedural success was obtained in 100% (130/130) of patients.
During the hospitalization period, 2 non-Q-wave myocardial infarction (non-QMI) events occurred post-procedurally due to branch occlusion.
Angiographic Results
Quantitative coronary analysis data are summarized in Table 4 . Pre-procedural lesion length was 12.78 mm. The stent/artery ratio was 1.14. The maximal final balloon inflation pressure was 12.9 atm. Pre-procedural RD was 2.68 mm. It significantly increased to 2.82 mm post-procedurally (p<0.05). At the 6-month follow-up, it significantly decreased to 2.37 mm (p<0.01). Changes in MLD and %DS are shown in Fig 1. Post-procedural MLD significantly increased from 1.00 mm to 2.24 mm (p<0.01). At the 6-month follow-up, it significantly decreased to 1.56 mm (p<0.01). Post-procedural %DS significantly decreased from 62.0% to 20.5% (p<0.01). At the 6-month follow-up, it significantly increased to 34.9% (p<0.01). Similar changes in both OC and SV stents were observed for MLD and %DS.
Clinical Follow-up Results
Clinical follow-up data are presented in Table 5 . At the 30-day follow-up, 1 non-QMI event occurred after the interventional procedure in another vessel. No subacute thrombosis was recognized. In the OC stent group, restenosis occurred in 15.6%, target lesion revascularization was performed in 12.2%, and target vessel failure occurred in 13.3% of the lesions. As mentioned above, 3 non-QMI events occurred. There was no death or CABG. In the SV stent group, restenosis occurred in 17.5%, target lesion revascularization was performed in 15.0%, and target vessel failure occurred in 15.0% of the lesions. There was no death, myocardial infarction or CABG.
Discussion
The current study shows that it is feasible to deliver the BiodivYsio stent safely at the target lesion site. Procedural success was obtained in all patients. These observations become increasingly significant when we consider more than half of the patients in the present study had complex coronary anatomies and lesions. We experienced 2 non-QMI patients post-procedurally due to side branch occlusions. Side branches of both cases were small. Therefore, angina and electrocardiographic changes after stent deployment were not remarkable. Side branch access through the stents was not attempted. However, serum creatine kinase levels rose to 648 and 733 IU/L on the following day, although abnormal Q-waves did not appear.
We experienced no thrombotic events in the current study. Some reports present the experience of the subacute thrombosis, [13] [14] [15] [16] [17] but the rates were equal or lower than previous reports using conventional metallic stents. 18 The PC polymer mimics the chemical structure of the PC headgroup, which makes up 90% of phospholipids in the outer membrane of a red blood cell. Phosphorylcholine has been shown to decrease protein absorption and platelet adhesion; thereby we can expect that the PC-coating reduces throm- bus formation of the stainless steel stent, allowing prevention of subacute thrombosis. The results from the current study affirms this hypothesis.
In the present study, patients with AMI were excluded. Galli et al demonstrated that primary stenting of AMI with PC-coated stent leads to excellent short and mid-term clinical outcomes and a low restenosis despite a reduced heparin therapy. 19 When we consider, first, that the PCcoated stents reduces thrombogenicity of the stents and second, that acute coronary syndrome (ACS) is strongly affected by thrombus, we might expect better results treat-ing ACS patients with this stent than those with stable angina pectoris. In addition, we may decrease post-procedural bleeding complications because of the short-term heparin regimen or the use of protamine sulfate when we use the PC-coated stents. 20 In the current study, a lower restenosis rate was shown, especially in small vessel lesions. As in previous studies, 16, 17 our study shows that the restenosis rate using the BiodivYsio stent in the small vessels is lower than those using any other metallic stents. [21] [22] [23] [24] [25] [26] Moreno et al represented the analysis of 11 randomized trials using conventional metallic stents in small vessels, including angiographic re-evaluation at 6 months. 26 According to this analysis, the pooled restenosis rate was 25.8%, which was worse than our data, 17.5%. It has been clearly demonstrated that the arterial diameter is one of the most powerful predictors of restenosis; however, in our study, the restenosis rate in lesions of small vessels (≤2.5 mm in diameter) were nearly equal to that of lesions in larger vessels (≥3.0 mm in diameter). Platelet derived growth factor is derived from activated platelet. It accelerates the intimal proliferation. Phosphorylcholine reduces the thrombus formation; therefore, PC might inhibit intimal proliferation and reduce restenosis. The suitability of this stent for small vessels is not only due to the PC-coating. There are few small vessel stents that are specifically designed for small diameter vessels. Most of the other small stents are produced with the same stent design as for large vessels mounted on smaller balloons. However, the BiodivYsio SV stent is specifically designed for small vessels and not simply mounted on a smaller balloon. Its diameter before dilatation is 1.0 mm, which is very small, and it has better deliverability than standard stents. Also, the stent strut thickness of the SV is very thin; 60.96 m.
Considering the previous reports, it is likely thinner struts have some benefits. 27, 28 Recently, drug-eluting stents (DES) have shown very promising long-term results. 29, 30 Preclinical and clinical studies of DES were shown to be safe and feasible in preventing neointimal hyperplasia, giving rise to a definite decrease in in-stent restenosis. However, small vessel size was shown to significantly increase the incidence of restenosis after sirolimus-eluting stenting in the SIRIUS trial. 31 Moreover, it is difficult to deliver the sirolimus-eluting stent to complex small vessel lesions because of the stent design. As mentioned above, the BiodivYsio SV stent has low restenosis rate and has excellent deliverability. Therefore, if we use the BiodivYsio SV stent as a platform of DES, we might be able to expect better results than what was attained in the SIRIUS trial for small vessels. In addition, DES cannot prevent sudden thrombotic occlusion, so the incidence of subacute stent thrombosis in patients using DES is not different from that with conventional metallic stents. [31] [32] [33] [34] Therefore, the BiodivYsio stent may be useful as a DES platform because PC can decrease thrombus formation. In fact, there are good data of the BiodivYsio dexamethasone-eluting stent. 35 Moreover, Virmani et al reported the possibility that the hypersensitivity to the polymer of sirolimus-eluting stent can cause late coronary thrombosis. 36 No hypersensitivity reaction to PC has been reported although the PC polymer has been used for a variety of devices including drain catheters, vascular grafts, artificial hearts, dialysis membrane, and contact lenses. The PC polymer has excellent biocompatibility. There is a possibility that the BiodivYsio PC-coating stent with drug elution may become the ideal DES because we can expect that the PC-coating prevents sudden thrombotic events and the eluting drug prevents restenosis.
Study Limitations
The obvious limitation of the current study is that it is an unblinded non-randomized pilot study without a balloon angioplasty or non-coated stent control group. It was performed in a selected small group of patients. Larger prospective randomized studies comparing non-coated stents and longer term follow-up are necessary to determine the essential role of PC-coated coronary stents. In addition, IVUS analysis was not performed in the present study. If we had used IVUS, it might have been helpful to analyze the tissue growth within the stents and to confirm the effect of PC in inhibiting neointimal tissue proliferation in human coronary arteries.
Conclusion
The BiodivYsio PC coated stent is safe and effective as a primary device for the treatment of native coronary artery lesions. Of particular interest, the present study showed no thrombotic events and good clinical results in small vessels. Although further studies would be necessary to draw a definitive conclusion, there is a possibility that the BiodivYsio PC-coating stent will become an ideal platform for DES.
